Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401213 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Safety Trial of MTX-463
A Phase 1 study, sponsored by Mediar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT06401213 is a Phase 1 study that has completed, run by Mediar Therapeutics. The registered enrollment target is 56 participants.
The verdict
NCT06401213, a Phase 1 study, has completed, sponsored by Mediar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.
Interventions
- OTHER Placebo
- BIOLOGICAL MTX-463
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2024-04-15 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06401213
The ClinicalTrials.gov registry entry for NCT06401213 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mediar Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06401213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06401213 about?
NCT06401213 is a clinical study titled "A First-in-Human Safety Trial of MTX-463". A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.
What is the current status of trial NCT06401213?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2024-04-15. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT06401213?
The interventions under investigation include: Placebo (OTHER), MTX-463 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06401213?
This trial is sponsored by Mediar Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.